Loading
A phase 3 trial of Nivolumab in melanoma, run by Bristol-Myers Squibb, active and no longer recruiting.
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma is a phase 3 interventional study registered as NCT04099251 by Bristol-Myers Squibb, with 790 participants enrolled, started 2019-10-28 and due to reach its primary completion in 2022-06-28. Interventions recorded: Nivolumab, Placebo. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma, Stage IIB and IIC melanoma, Melanoma.
Shares Bristol Myers Squibb, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/